Abstract
Purpose
Platinum-based doublet chemotherapy and radiotherapy are the standard treatment option in advanced squamous cell carcinoma patients. However, few agents could be selected for subsequent post-second-line treatment. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, apatinib had been proved in advanced gastric cancer. Here, we showed its efficacy and safety in lung squamous cell carcinoma.
Methods
In this retrospective study, 13 advanced lung squamous cell carcinoma patients were enrolled. They received doublet chemotherapy or docetaxel as the first-line treatment. After disease progressed, all patients were administrated apatinib monotherapy (250–425 mg/day) for second-line or fourth-line therapy.
Results
After apatinib monotherapy, two patients achieved partial response, four patients achieved stable disease, and seven patients achieved progression disease. The medium PFS was 3.1 months. The median OS had not yet been reached. The objective remission rate was 15.4% (2/13). The total disease control rate was 46.2% (6/13). The main advert effects were vomiting and hypertension.
Conclusion
Apatinib might be an option as rescue treatment in advanced lung squamous cell carcinoma.
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2QTjIjm
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου